Jerusalem Report - Abstract (Document Summary)
here is part of the article...
Blood Breakthrough?
The Jerusalem Report - Jerusalem Author: Hanan Sher Date: Mar 19, 2007 Start Page: 28 Section: Business Text Word Count: 1941
Abstract (Document Summary)
About 50,000 bone marrow and peripheral blood transplants and only 1,000 umbilical cord transplants are performed each year, though a 2004 University of Wisconsin study shows that the cord blood is almost equally effective. The disparity, [Aberman] explains, is due to the slower time of engraftment, the acceptance of the donated cells into the patient's body and the production of new cells to replace those that have been intentionally eliminated.
The company, he says, "discovered an oil field in the placenta," suggesting that, after development of PLX 1, there may be other medical applications for placental cells. The first, after engraftment, is what is known as graft-vs.-host-disease (GVHD), the rejection of the transplanted marrow which affects about half of all patients who get bone marrow transplants. In about 25 percent of the cases, where the new cells attack the body of the patient, the outcome is fatal. Beyond that, Aberman shies away from speculating that his technology may provide the key to treatments of a variety of other afflictions, possibly including Alzheimer's and Parkinson's. "But I can say that mesenchymal cells derived from bone marrow can be helpful in treatments for a variety of diseases, and we hope that our mesenchymal cells can do the same, if not with all diseases then with some of them."
Aberman estmates that he can cut the transplant price to $10- $15,000 for the matching umbilical cord cells themselves, and another $15,000 for the Pluristem product. "People in the business have suggested that I can charge $40,000 or $50,000, but I don't think that's right. If you want 100,000 people to use it, you had better charge a reasonable price, like $15,000," he says.
|